113 documents

Read All
15:24 , Jun 8, 2018 |  BC Week In Review  |  Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

RXi Pharmaceuticals Corp. (NASDAQ:RXII) and Iovance Biotherapeutics (NASDAQ:IOVA) will evaluate combining RXi's self-delivering RNAi technology with Iovance's Tumor Infiltrating Lymphocytes (TILs) in the treatment of solid tumors. The partners said the combination will be "explored...
Read More
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
Read More
19:46 , Jul 5, 2017 |  BC Week In Review  |  Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

RXi Pharmaceuticals Corp. (NASDAQ:RXII) completed enrollment of about 9 patients with advanced wet age-related macular degeneration (AMD) in the Phase I/II Study RXI-109-1501 evaluating once-monthly intravitreal RXI-109 for 4 months to reduce the progression of...
Read More
12:29 , May 26, 2017 |  BC Week In Review  |  Company News

PCI, RXi extend preclinical collaboration

PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and will conduct new studies to assess the compatibility of the companies’ immuno-oncology technologies. The partners said they will conduct...
Read More
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration. The continued...
Read More
01:00 , Dec 21, 2016 |  BC Week In Review  |  Financial News

RXi completes follow-on

RXi raised $10 million through the sale of 2.1 million class A units at $0.90 and 8,082 class B units at $1,000 in a follow-on underwritten by Ladenburg Thalmann and Griffin Securities. Each class A...
Read More
21:25 , Nov 15, 2016 |  BC Week In Review  |  Financial News

RXi amends follow-on

RXi amended its follow-on and now plans to sell 2 million class A units and 9,600 class B units. The company also added Griffin Securities as an underwriter; Ladenburg Thalmann is also an underwriter. The...
Read More
07:00 , Oct 31, 2016 |  BC Week In Review  |  Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass.  Business: Gene/Cell therapy, Dermatology, Ophthalmic  Date announced: 2016-10-21  Type: Follow-on  To be raised: Up to $20.7 million  Units: TBD  Price Prior: $1.19  Underwriter: Ladenburg Thalmann  Note: Each class A unit comprises shares and warrants to purchase shares....
Read More
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

MirImmune, RXi Pharmaceuticals deal

RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a 19.99% stake in RXi and would be eligible for undisclosed milestones. The stake is valued at about $2.2 million...
Read More
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, Thera Neuropharma deal

Thera Neuropharma licensed exclusive rights to RXi’s sd-rxRNA platform to develop and commercialize therapeutics for neurodegenerative diseases. Thera Neuropharma plans to initially focus on developing compounds targeting superoxide dismutase 1 (SOD1) to treat amyotrophic...
Read More